Prognostic value of the modified advanced lung cancer inflammation index in overweight or obese patients with lung cancer: Results from a multicenter study

Abstract Background This study aimed to explore the relationship between the modified advanced lung cancer inflammation index (mALI) and the survival of overweight or obese patients with lung cancer (LC). Methods The mALI was defined as the appendix skeletal muscle index multiplied by the serum albumin level/neutrophil‐to‐lymphocyte ratio. The cutoff values for males and females were assessed separately. Survival curves were estimated using the Kaplan‐Meier method, and statistical differences were determined using the log‐rank test. Univariate and multivariate Cox proportional hazards models were used for the survival analysis. The area under the receiver operating characteristic curve was used to compare the prognostic value of mALI with other nutrition assessment indicators. Results The mALI cut‐offs for males and females were 8.59 and 8.26, respectively. Malnutrition, high systemic inflammation, and advanced stage for overweight or obese LC patients were found to be correlated with a low mALI. The median survival of patients with a low mALI was significantly lower than patients with a high mALI by approximately 25 months. In addition, the mALI can be used as an effective supplement to the traditional pathological stage. Multivariable analysis found that mALI was an independent prognostic factor of overall survival (hazard ratio = 0.531; 95% CI, 0.402–0.700; P < 0.001). The prognostic predictive performance of mALI was superior to that of other nutrition assessment indicators. Conclusions The mALI was an independent risk factor for the prognosis of overweight or obese LC patients, and a useful supplement to the pathological stage.